Butorphanol Tartrate MINImix™ Tablet
Butorphanol Tartrate is an FDA-approved preparation containing Butorphanol Tartrate, for veterinary use. Available by prescription.
Veterinarians most commonly consider butorphanol tartrate in the context of acute pain management for short-term procedures or minor traumatic injuries. It is also frequently a point of discussion for canine respiratory protocols, where its antitussive (cough-suppressing) properties are a clinical objective for pets presented with tracheobronchitis or localized airway irritation. In feline and equine patients, veterinarians may discuss butorphanol as a component of sedative protocols, often pairing it with other medications to facilitate patient handling or minor diagnostic interventions.
At a pharmacological level, butorphanol functions as a mixed agonist-antagonist. It acts as a potent agonist at kappa-opioid receptors and as a partial agonist or antagonist at mu-opioid receptors. By stimulating the kappa receptors, the medication manages the transmission of discomfort signals within the central nervous system. Its activity at the mu receptors contributes to its "ceiling effect," meaning that after a certain point, increasing the dose does not produce a significant increase in sedation or respiratory depression. When utilized for its antitussive effects, it acts directly on the cough center in the medulla of the brain. Your veterinarian will determine whether this medication is appropriate based on the species, the specific clinical objective and the results of a physical examination.
The actions described here reflect the product's FDA-approved labeling; your veterinarian determines the appropriate use for your animal.
Prescription only. Use only under the direction of a licensed veterinarian. This information is not a substitute for veterinary diagnosis, prescribing or monitoring.
Commonly observed effects following the administration of butorphanol include sedation, decreased appetite and localized digestive changes. In some pets, veterinarians have observed behavioral shifts such as mild agitation or dysphoria, while horses may exhibit localized tremors or increased sensitivity to sound. Because it suppresses the cough reflex, owners should watch for any changes in breathing patterns or excessive lethargy and contact their veterinarian promptly if these occur.
This medication is typically used with extra caution or avoided in patients with known severe hepatic disease, head trauma or pre-existing respiratory compromise where a cough may be physiologically necessary. In certain breeds, such as Collies or Australian Shepherds, a specific genetic profile (MDR1 mutation) may influence how the pet processes butorphanol, requiring specialized veterinarian-directed monitoring. Before starting a protocol, ensure your veterinarian has a complete history of all other prescriptions your pet is receiving, as interactions can occur with other central nervous system depressants or certain antifungal medications. Your veterinarian is the right person to provide guidance on the necessary duration of use and the proper monitoring schedule to ensure the management approach remains suitable for your pet's individual needs. Always consult your veterinarian about the appropriate duration of use and whether your horse's competitive status requires a withdrawal period. Butorphanol (an opioid analgesic) is subject to detection in equine medication-testing programs and specific withdrawal times vary by jurisdiction and governing body.
Yes. Butorphanol tartrate is a prescription medication and a controlled substance, meaning it can only be dispensed by a licensed pharmacy upon receipt of a valid authorization from a licensed veterinarian. Mixlab verifies all veterinarian-client-patient relationships before any medication is dispensed.
Yes. While butorphanol is available in commercial injectable and tablet forms, Mixlab can compound the active ingredient into customized strengths and flavored dosage forms—such as oral liquids or chewable may be considered in cases of—to better suit an individual patient's needs. The decision between a commercial and compounded product rests with the prescribing veterinarian.
Veterinarians discuss butorphanol for dogs with persistent, non-productive coughs because it acts directly on the brain's cough center to suppress the reflex. This approach is often considered when a cough is causing physical exhaustion or interfering with a pet’s ability to rest and recover.
Sedation is a common and effect of butorphanol, and veterinarians often utilize this property to help pets remain calm during recovery. While a degree of sleepiness is expected, you should report any signs of profound lethargy or difficulty waking up to your veterinarian immediately.
